For the study, researchers examined antibody response in 37 Chinese patients who were hospitalized for COVID-19 but did not have symptoms. Researchers compared their antibody response to that of 37 symptomatic patients.
Within eight weeks of hospitalization, 81 percent of asymptomatic patients had decreased antibody levels, compared to just 62 percent of symptomatic patients. Within this time period, antibody levels fell to undetectable levels in 40 percent of asymptomatic patients and 12.9 percent of symptomatic patients.
The findings suggest asymptomatic patients may have a weaker immune response to the virus, researchers said.
While the study is limited by its small sample size, it could complicate the idea of giving “immunity certificates” to people who’ve recovered from COVID-19, reports The New York Times.
To view the full study, click here.
More articles on public health:
3 likely reasons Ohio hasn’t seen COVID-19 surge weeks after reopening
Where new COVID-19 cases are rising, falling and staying the same — June 18
COVID-19 surge strains Alabama hospitals; employers can’t require antibody testing, EEOC says — 7 updates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
